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Traumatic brain injury (TBI) has been identified as an important cause of death and
severe disability in all age groups and particularly in children and young adults. Central
to TBIs devastation is a delayed secondary injury that occurs in 30–40% of TBI patients
each year, while they are in the hospital Intensive Care Unit (ICU). Secondary injuries
reduce survival rate after TBI and usually occur within 7 days post-injury. State-of-art
monitoring of secondary brain injuries benefits from the acquisition of high-quality and
time-aligned electrical data i.e., ElectroCorticoGraphy (ECoG) recorded by means of
strip electrodes placed on the brains surface, and neurochemical data obtained via
rapid sampling microdialysis and microfluidics-based biosensors measuring brain tissue
levels of glucose, lactate and potassium. This article progresses the field of multi-modal
monitoring of the injured human brain by presenting the design and realization of
a new, compact, medical-grade amperometry, potentiometry and ECoG recording
bioinstrumentation. Our combined TBI instrument enables the high-precision, real-time
neuroelectrochemical monitoring of TBI patients, who have undergone craniotomy
neurosurgery and are treated sedated in the ICU. Electrical and neurochemical test
measurements are presented, confirming the high-performance of the reported TBI
bioinstrumentation.
Keywords: analog-to-digital conversion, bioinstrumentation, biosensors, microdialysis, microfluidics, traumatic
brain injury
1. INTRODUCTION
In the UK an estimated 238,000 people suffer from a TBI each year (Whitfield et al., 2009).
Most are stabilized in an ICU at a cost of approximately £2000 per day for extended periods
before discharge, often with life-changing disability. Estimates of annual UK mortality vary
considerably, but it is likely that approximately 4000–7000 people die. In the US an estimated
1.7 m people suffer from TBI annually. Of these 52,000 die and 275,000 are hospitalized. A third
of all injury-incurred deaths in the US relates to TBI (Faul et al., 2010) with the TBI-related
healthcare cost exceeding $3 bn (Russo and Steiner, 2007; Langlois et al., 2006). Moreover, around
1,000,000 hospital admissions each year in the European Union alone are due to TBI (International
Brain Injury Association). The Lancet Neurology recently termed TBI a “silent epidemic,”
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in an attempt to highlight the importance of this intracranial
injury and underline the need for accurate, state-of-the-art
medical systems that can assist clinicians with early diagnosis
and efficient treatment (Editorial, 2010; Lingsma et al., 2010).
Main role to the disability and mortalities caused by the TBI is
played by an indirect, often delayed result of the primary brain
injury, known as “secondary brain injury.” This post-traumatic
complication can occur up to a week after the initial incident,
which defines a clear treatment window. However, up to now,
there is no robust method able to predict, when secondary brain
injury begins, thus, effective timely treatment is not given.
The ability to measure minute signals reliably from the
traumatized brain will allow clinical staff to detect (and
perhaps ultimately predict) the onset of secondary brain injury.
Combined dynamic monitoring techniques such as ECoG and
real-time sampling of brain glucose by means of microdialysis—
which shows that intense spontaneous waves of depolarization
(SD waves) spread out from the initial site of injury into the
surrounding brain tissue driving down the brain energy supply
of glucose—will collect more useful sets of data from patients,
resulting into a more effective treatment approach, tailored to
each patient’s unique condition. In order to exploit the most
out of the aforementioned physiological monitoring techniques,
a high-performance interfacing circuitry is required, where
the signals provided by the various sensors will be processed
continuously with as little noise interference as possible, thus,
leading to an as high as possible signal-to-noise ratio (SNR).
The main goal of this article is to introduce a new generation
of TBI monitoring instruments, capable of acquiring weak/small
chemical and electrical signals from the traumatized human
brain, in a low-noise, high-accuracy manner. These instruments
interface with high-caliber amperometric and potentiometric
biosensors, as well as with certain types of electrodes. Depending
on the type of the biosensor, the output signal for a given
substrate concentration is either a constant current or voltage.
In biochemistry, the most common techniques used to read-out
these types of biosignals with the help of (usually off-the-shelf)
electronic equipments are mainly two: (i) using a transimpedance
amplifier (TIA), i.e., a current-to-voltage converter (I-V) for
the current input signal (generated by an amperometric sensor)
and (ii) using a high common-mode-rejection-ratio (CMRR)
instrumentation amplifier (V-V) for the voltage input signal
(generated by a potentiometric sensor) with a specific, usually
high, differential gain.
For sensitive TBI monitoring related biosignals, the
aforementioned I-V and V-V conversion circuit techniques
may exhibit various inaccuracies, mainly due to the strong
presence of noise, once implemented on a Printed Circuit Board
(PCB) with commercially available components. Unlike the
conventional biosensor read-out methods, our instruments
exploit the use of appropriate current- and voltage-input analog-
to-digital converters (ADCs), in order to acquire and process
TBI-related biosignals in a low-noise manner and immediately
convert them into noise-insensitive digital signals. Comparative
experimental/measured results between the traditional and
the proposed techniques implemented by the new electronic
platforms are presented and discussed in depth.
The article is structured as follows: Section 2 offers a
brief, but inclusive introduction to the dynamic monitoring
materials and methods of secondary brain injury detection.
The various types of sensors been used in each monitoring
category will be also illustrated, accompanied by the appropriate
information regarding their operation. Moreover, in the same
section the reader can find a detailed discussion of the
proposed electrical and neurochemical biosensor interfacing
data acquisition electronic platforms. Section 3 deals with the
presentation of the various experimental results obtained from
the different types of biosensors. Finally, the paper concludes
with Section 4, where a detailed discussion can be found
accompanied by the analysis of the measured data and their
significance in TBI patients monitoring. Moreover the limitation
of the specific instrumentation are discussed and envisaged
future applications are proposed.
2. MATERIALS AND METHODS
2.1. Detection of Possible Causes of
Secondary Brain Injury
Brain injuries should not be treated as single events, but
as complex, subsequential processes which contain multiple
interplays of different effects, such as structural damage, regional
ischemia, inflammation, and metabolic crisis (Obrenovitch and
Urenjak, 1997; Holmin et al., 1998; von Oettingen et al., 2002;
Vespa et al., 2005; Kurland et al., 2012). Without effective
treatment and a complete understanding of the traumatic brain
injury, the pathological features of TBI will cause patients to
suffer from secondary brain injuries, which may be even more
damaging. Approximately 40% of patients admitted to hospital
with TBI will suffer from secondary brain injury (Narayan
et al., 2002). Commonly used covariates, such as age, pupil
activity and motor score, can only explain 30% of the variance
in TBI outcome (Murray et al., 2007). To identify patients
most at risk of developing secondary brain injury, we suggest
a monitoring system that will combine results from both the
electrical activity, using ECoG, and the neurochemical recordings
by using biosensors coupled to a microdialysis probe. Currently,
a “wait and see” approach is taken with any secondary injury
managed after its development. CT and MRI scans provide
information about the brain tissue at that particular moment
in time but fails to indicate which patients are likely to suffer
from secondary brain injury. A multi-modal bedside system will
provide valuable information to the clinicians about the brain
tissue directly and continuously over the monitoring period.
Accessing this information, allows clinicians to act prior to
the development of secondary brain injury and potentially will
provide a more personalized approach to clinical care.
2.1.1. Through Electrical Activity Recordings—ECoG
Method
Spreading depolarizations (SD) waves were first identified in
1944 by Leao [Leao (1944)] and the presence of SD waves
in brain injury patients has since been identified as a good
predictor of secondary brain injury and poor patient outcome
(Hartings et al., 2011). SD waves are the outcome of mass
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neuronal and astrocytic depolarization that mainly originate
from ischemic brain injury and propagate across the cerebral
cortex. These types of waves occur frequently to patients who
are undergoing a craniotomy, which is often required when a
sub-arachnoid hemorrhage (SAH), TBI, malignant hemispheric
stroke, or spontaneous intra-cerebral hematoma is taking place
(Strong et al., 2005; Dohmen et al., 2008; Lauritzen et al., 2011;
Woitzik et al., 2011). A reliable method to detect and characterize
SDwaves can be provided by ECoG and is seen as a slow and huge
negative potential drop, which silences the electrical activity of
the cortex. Compared to typical electroencephalography (EEG)
signal recordings, which are acquired from the scalp (and
therefore are attenuated due to the low conductivity of bone),
the ECoG signal is captured directly from the exposed surface
of the cortex and thus, offers much higher spatial resolution. The
approximate spatial resolution of ECoG monitoring is 1 cm with
a temporal resolution of 5 ms (Asano et al., 2005).
In terms of detecting and monitoring the ECoG signal, two
different types of electrodes have been reported in the literature,
presented in Figure 1; the strip electrode (Strong et al., 2002) and
the depth electrode (Jeffcote et al., 2013). The strip electrodes
are placed directly onto the cortex of the brain when the patient
undergoes the craniotomy, and therefore this technique, and
hence the monitoring of SD waves, is restricted to those patients
who require craniotomy. Whereas, the depth electrode array
allows the ECoG signal, and SD waves, to be monitored via a
burr hole to the cortex. This technique does not require patients
to undergo major surgery and the burr hole procedure can be
conducted on the intensive care ward. This method facilitates the
monitoring process and the number of available patient samples.
The cortex SD (CSD) wave that is recorded by the ECoG
signal is characterized by a low and a high frequency range.
In the low-frequency range of the ECoG, almost direct current
(DC) range, the CSD can be seen as a negative potential shift,
while in the high-frequency range of the ECoG, CSD causes
silencing of spontaneous activity (spreading depression). The
vast majority of clinical studies have used an alternating current
(AC)-ECoG setup in the ∼0.5–100 Hz range (“high” frequency
range). In practice, AC coupling requires the transition of the
raw ECoG signal through an ordinary capacitor, of appropriate
value. The AC-coupling of the ECoG signal generates a high-pass
FIGURE 1 | Typical depth (upper one) and strip (lower one) electrodes,
commonly used in ECoG method for TBI (photo kindly provided by Dr.
Toby Jeffcote).
filter (with behavior corresponding to the time-constant dictated
by the capacitor) which eliminates the DC component of the
raw ECoG signal. On the other hand, a DC-ECoG signal allows
both frequency band components of the CSD wave to pass
and subsequently be measured by appropriate data-acquisition
systems. DC-ECoG measurements are more favorable compared
to AC-ECoG data, since more information about the traumatized
brain is included in the signal. Indicative publications of AC-
ECoG and DC-ECoG measurements can be found in Hartings
et al. (2009) and Oliveira-Ferreira et al. (2010), respectively.
2.1.2. Through Neurochemical Changes Recordings
Previous work has led to the development of a rapid-sampling
microdialysis technique (rsMD) to measure brain tissue glucose
and lactate levels in real-time (Parkin et al., 2005). This work
involves the use of a microdialysis probe to sample the tissue in
which it is placed. Traditionally, the liquid sample is collected in
a vial, which is inserted into a bedside analyser by hand every
hour. The analysis component of rsMD, however, connects to
the microdialysis probe via a long, fine bore connection tubing
and analyses nanoliter samples, online, every minute. The results
from the use of rsMD in both surgery (Bhatia et al., 2006) and
whilst monitoring on the ICU (Feuerstein et al., 2010) have
proved that there are key neurochemical changes, which are
detrimental to the brain tissue outcome that occur on this time
scale.
rsMD consists of a mechanical valve connected to
electrochemical detectors for glucose and lactate. There is a
need for a chemical marker of depolarization as the electrical
probes (electrodes) and the microdialysis probes cannot measure
the same space within the tissue. Therefore, there is an error
in time aligning the data and currently it is based on the
approximate location of the probes as seen on scans such as MRI.
The analysis equipment, plus all of the associated equipment,
are placed upon a large trolley that can be wheeled to the
patient when required and ideally, the trolley and the associated
equipment need to be smaller to be practical in a busy ward and
theater. Also, the connection tubing means that there is a time
delay from sampling to analysis (rsMD takes approximately 15
min, due to low flow rates) and dispersion occurs, smearing out
any fast sharp changes and increasing the difficulty in analysis.
Therefore, work has been undertaken to miniaturize the system
and address these key problems.
The application of microfluidic platforms to microdialysis use
is a recommended one. Microfluidic platforms can easily handle
the nanoliter-sized samples gained from microdialysis and will
miniaturize the analysis system. The use of digital microfluidics,
i.e., the addition of an immiscible oil flow to segment the dialysate
into tiny droplets, eliminates dispersion as droplets do not mix
together, and the faster flowing oil reduces the time lag to
seconds without affecting the flow rate through the microdialysis
probe (Rogers et al., 2011). Smaller electrochemical biosensors
for glucose and lactate, and ion selective electrodes (ISE’s) for
potassium, a chemical marker for depolarization, have been
tested for such a purpose (Rogers et al., 2011, 2013b). Indicative
types of the aforementioned biosensors and experimental setups
are shown in Figure 2.
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FIGURE 2 | (A) The glucose biosensor setup, (B) the tip of the needle electrode and (C) a potassium ion selective electrode (ISE), all produced by the Boutelle Lab.
The LabSmith components (also known as “uDevices”) are including valves, syringe pumps, manifold (used to control the valves), and the platform (provides
interconnections of these components and the host PC). The PDMS chip is applied to convey the dialysis samples (glucose, lactate, etc.) in the microdialysis tube to
the sensors, using microfluidic techniques. Finally, the combined needle integrates the three-electrode system in a single tip. The difference between an electrode and
a sensor lies within the application of different enzymes. (A) Combined needle electrode placed onto a PDMS microfluidic chip within the LabSmith automated system.
(B) Combined needle with three electrodes. (C) Potassium ISE.
SD waves have a clear neurochemical effect on the tissue.
There is a wave of hyperaemia associated with the depolarization
events (Leo, 1944). The depolarization of all the cells in the local
area, places a huge demand on energy sources to repolarize the
cell membranes. It has recently been shown in a translational
study (Rogers et al., 2013b) that the energy demand to repolarize,
causes local glucose concentrations to decrease and that this
demand is not met by local blood flow due to the hyperaemic
wave passing the cells during the depolarization stage. This deficit
in glucose availability forces the cells into anaerobic respiration
and hence the concentration of lactate increases. The lactate to
glucose ratio has been shown to be a good indicator of ischemia
and tissue health (Rogers et al., 2013a).
In patients, monitoring the levels of glucose and lactate in the
nearby at risk tissue of TBI patients using rsMD has shown that
the glucose levels decrease and the lactate levels increase with
corresponding evidence of SD waves (Feuerstein et al., 2010).
It has been hypothesized that the local pools of glucose are
slowly being diminished with each event, possibly falling to an
insufficient level to sustain the cells. It is this effect which may be
attributing to the growth of ischemic tissue and secondary injury
in the surrounding tissue (Feuerstein et al., 2010).
2.2. Next Generation of Neurochemical and
ECoG Instrumentation for TBI Monitoring
Potentiometric sensors, such as the potassium ISE, can in practice
be considered as constant voltage sources in the mV range
connected in series with a source resistance, which strongly
depends upon the fabrication and configuration of the sensor.
A typical value of the potentiometric source resistance ranges
between 106 − 109 Ohms. On the other hand, a typical
amperometric biosensor can be considered as a high-impedance
picoampere (pA) to nanoampere (nA)-level current source (Yue
et al., 2008). Thus, the input impedance levels of the sensor
interface circuitry should be selected appropriately.
For potentiometric sensors, the values of their output signal
range between few hundreds of µV up to few hundreds of
mV . Miniaturized TBI amperometric sensors usually provide an
output current signal that ranges between some tenths of pA
up to few nA. For amperometric sensors, a conversion of the
sensor current input signal into a voltage one using a TIA stage
is very common, while for potentiometric sensors, the use of
instrumentation amplifiers of fixed/tunable gain that produce an
output signal that it is generated by a potential difference between
the input and a reference signal is also trivial. It should be
stressed that for such current levels, the effect of the thermal noise
generated by the usually high in value feedback resistor (typically
hundreds of MOhms up to several GOhms) of the traditional
transimpedance setup, compromises the integrity of the recorded
amperometric biosensor signal, despite its very low bandwidth
(Glaros and Drakakis, 2013).
The impact of noise upon the measurements can be reduced
by introducing analog or digital filtering. However, in general,
filtering may also affect or even eliminate (depending on the
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type, order and band of operation) from the finally recorded data
clinically crucial physiological information present in the noisy
raw signal(s). TBI-related biosignals contain crucial physiological
information in their “raw form.” In order to tackle the effect
of the thermal noise of the resistor of a TIA setup upon
the amperometric sensor current signal, the switched-capacitor
paradigm has been adopted (Liu, 2006), where the input current
charges a capacitor, whose charging and discharging phases
are controlled by a combination of switches in the recording
circuit. This technique does not call for an ohmic resistor.
Hence, the integrity of the input current is not compromised
by the significant levels of thermal noise due to the high-valued
transimpedance resistors. In Figures 3A–D, the interested reader
can find four typical configurations of a characteristic switched-
capacitor recording topology.
An off-the-shelf integrated circuit chip that combines the
aforementioned switched-capacitor technique with a high-
precision, current input ADC is the DDC family chip series
produced by Texas Instruments. For the design of our TBI
boards, the quad-channel DDC114 chip has been selected. These
20-bit current-input ADCs provide adjustable full-scale ranges
and integration times that allow currents from hundreds of fA
up to few µA to be measured with sufficient precision. Moreover,
the dual-switched integrator front-end of this chip series, allows
for continuous measurement (current integration) of the input
current signal, since while one integrator is being digitized by
the chip’s ADC, the other one is integrating the input current.
A simplified architecture of the DDC family chip is illustrated in
Figure 3E.
With the use of the switched-capacitor technique for
amperometric sensor measurement, we reduce drastically the
presence of noise in the recorded amperometric data. For the
voltage signals originating from the potentiometric ISE and
ECoG electrodes presented in Section 2.1, another off-the-
shelf, low-noise, high-accuracy integrated circuit solution from
Texas Instruments has been chosen to interface with them,
the ADS1298 family chip. Comprised of highly flexible input
multiplexers per channel that can provide many configurable
signal switching options, these fully-differential, multichannel,
simultaneously-sampling, 24-bit resolution delta-sigma (16)
ADCs are accurate, programmable chips that can easily detect
minute potential changes and record them efficiently without
introducing excessive noise or offset. The differential signal
of each of the 8 channels of the ADS1298 benefits from
a programmable gain amplifier (PGA), while high-resolution
16 ADCs follow. The high precision of the specific chip in
FIGURE 3 | The switched-capacitor technique exemplified by four typical configurations of a typical switched-capacitor circuit. Proper ON/OFF
combinations of the five different switches illustrated in the Figure, result to a different state of the circuit. Panel (E) provides a simplified block diagram configuration of
the current-input ADC, which exploits the switched-capacitor architecture and has been selected to interface with the amperometric biosensors. (A) Reset
configuration. (B) Wait configuration. (C) Integrate configuration. (D) Convert configuration. (E) A simplified architecture of the DDC family chip.
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conjunction with its high accuracy properties leads to low-noise
high accuracy measurements even for very small input signals (in
the range of few µVs).
With the help of the aforementioned current/voltage input
ADCs, an alternative high-performance approach to the read-
out of TBI-related biosignals has been adopted. Immediate
digitization of the analog biosignal allows us to further process
the captured signal by digital means, and therefore, without
minimal corruption by the various noise sources of the
environment (Park and Mackay, 2003).
2.2.1. Neurochemical Biosensor Interfacing Circuit
Board
Figures 4A,B illustrate the operational architecture and the
physical realization of the neurochemical TBI board. Three
different biosensor front-end interfacing areas have been realized:
(a) the amperometry section comprising four current input,
ADC chips of the DDC family, each one responsible for the
monitoring of mainly two different types of biosensors, i.e.,
glucose and lactate biosensors. The four current-input ADCs
can support the high-performance, low-noise, simultaneous
interfacing with eight in total amperometric biosensors; (b)
the TIA section, which offers conventional I-V read-out of
up to four amperometric biosensors, generating currents in
the range of tenths of nAs. The TIA interface comprises low-
input bias and offset current-opamps and high-valued, ultra-
high-precision resistors. The input bias current of the high
precision amplifier is in the range of few femptoamperes (fAs);
(c) the potentiometry section enabling the interfacing with up
to four potentiometric biosensors. The potentiometry channels
involve low-offset, high-input impedance opamps. Eight in
total (four corresponding to the TIA section and four to the
potentiometry section) interfacing channels, whose output is
of voltage form are converted by the aforementioned voltage-
input ADC chip (see Figures 4A,B). Referring to the same
Figures (see bottom right side of Figure 4B), the Spartan3e
series FPGA from Xilinx has been employed for the control
and programming of the seven in total converters [ADCs and
Digital-to-Analog converters (DACs)] of the board as well as
for the Digital Signal Processing (DSP) of the digital data. The
FPGA is clocked from a 64MHz clock module and can be
programmed via USB2.0 interface. DACs are used (see center
of Figure 4B) for the controlled and programmable generation
of the appropriate reference electrode voltage levels. Bearing
in mind the regulations governing medical instrumentation,
medically approved powering-up modules (AC/DC and DC/DC
converters) are employed (see top of Figure 4B).
The last but not least compartment of the neurochemical
board is the electrically isolated area located at the top right part
of the board (see Figure 4B). This area is protected from the rest
of the board by the existence of a physical gap of 2 mm drawn
around every power plane of the board, while all the digital lines
that connect the FPGA with the output DAC that is projecting
the measured input signal are passing through two 5 kV RMS
quad-channel, high-speed digital isolators. This section of the
board can be seen alternatively as a separate PCB “nested” inside
the neurochemical board, since there is no electrical connection
between this section and the rest of the board. This section is
operating with its own power and ground planes. The “nested”
PCB aims at minimizing digital switching noise to the rest of the
board, while also contributing to the patient isolation. A USB
digital isolator has also been employed, in order to electrically
isolate the board from the patient/user.
The board comprises eight different signal and power
layers/planes with the front-area of the top layer—which
hosts the DDC amperometry, the TIA amperometry and
the potentiometry section (see Figure 4A)—been fabricated
using Rogers RO4350B material, an advanced PCB material
characterized by and ultra high resistivity of 1012Ohms, instead
of the typical FR4 material. RO4350B minimizes any leakage
currents between the sensor outputs and the converters. In
addition appropriate guard rings have been placed around the
input connectors interfacing with the biosensors. The board has
been designed with a certain level of intentional redundancy.
Referring for example to Figure 4A, it can be seen that the
collected digitized data are output through an appropriate DAC
as analog channels (shaded part of Figure 4A). This allows
for the interfacing of the proposed board with visualization
suites (such as Powerlab R©) enabling the time-aligned, concurrent
illustration of dynamic physiological data. Table 1 summarizes
the characteristics of our neurochemical board for TBI.
2.2.2. Electrocorticography (ECoG) Circuit Board
The ECOG platform comprises three different boards: the digital
signal processing board and two front-end boards, a unipolar and
a bipolar one (see Figure 5). These two front-end boards have
practically the same architecture, however, they perform different
types of ECoG measurements. When the depth electrode is used
for an ECoG measurement, unipolar measurements take place,
where the eight channel inputs from the depth electrode are
subtracted from a ninth reference electrode, located at a specific
area of the scalp. When the strip electrode is used, bipolar
measurements take place, where the six signals/channels of the
strip electrode are subtracted in a sequential form.
Figure 5A shows the operational architecture of the ECoG
data acquisition platforms. Figures 5B,C illustrate the fabricated
ECOG boards. The front-end board shown in Figure 5B
is a bipolar ECoG board: six low-power, high-precision,
non-inverting amplifiers and voltage buffers “feed” the ADS
family chip, which converts the collected ECoG data into digital
signals (the reader should note that the unipolar board shown
in Figure 5A has similar architecture). Both the bipolar and the
unipolar boards are connected to the digital signal processing
board by means of RJ45 cables, through high performance digital
signal isolators, which ensure the patients protection from any
unwanted currents or voltages. The digital signal processing
board comprises a Spartan3e FPGA and two eight-channel
output DACs, which enable the real-time visualization and
post-processing of the collected ECoG data by mature clinical
monitoring modalities, such as Powelab R©.
The “splitting” of the ECoG monitoring system into two parts
favors noise reduction and preservation of the signal’s integrity.
The front-end board has been designed to be battery-operated
(which further favors noise reduction compared to power-supply
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FIGURE 4 | The TBI neurochemical biosensor interfacing circuit board. In (A) a simplified architecture diagram of the board can be seen, while in (B) the actual,
fabricated electronic platform is shown, with its distinct compartments annotated on the Figure. (A) Operational block diagram of the TBI neurochemical data
acquisition platform. (B) The neurochemical board with its eight distinct compartments.
Frontiers in Human Neuroscience | www.frontiersin.org 7 May 2016 | Volume 10 | Article 212
Papadimitriou et al. A Novel High-Performance TBI Bioinstrumentation
TABLE 1 | Electrical characteristics of the neurochemical TBI board.
Sections
Characteristics Sw. Cap.
Amperometry
T.I.A.
Amperometry
Potentiometry
Number of input
channels
8 4 4
Resolution (bits) 16/20 – 24
Data rate (kSPS) 3.125 – 0.5–32
Input bias current (pA) 0.1 0.003 0.2∗
Total analog current
supply (mA)
∼ 56 ∼ 5.2 ∼ 15.1
Total digital current
supply (mA)
∼ 2 – ∼ 0.5
Number of analog
output channels
24
Board dimensions (cm) 23 × 19
Medically graded Yes - using power/digital signal/USB isolators
IC controller Spartan3e - 64 MHz - FPGA
Power supply 220V AC, 50 Hz
*This is the input bias current of the analog circuitry before
the voltage-input ADC.
powered solutions) and to be placed very close to the patient’s
head (ideally on the scalp), while the digital signal processing
board can be placed relatively far away from the patient (∼
2 m away), thus, the amplification and immediate digitization
of the data takes place close to the patient, as less affected by
any potential noise sources in the ICU. Subsequently, the noise-
immune digitized ECoG signals are exported through the RJ45
cables to the digital signal processing board for visualization
and post-processing. If the ECoG boards were not split from
the DSP board, then the weak raw ECoG signals would first
need to be conveyed through a 1–2 m cable (which makes them
more susceptible to noise since they are still in analog form)
to the combined “front-end/DSP” board fabricated on the same
substrate and powered-up by a noisier power source. Such a
solution would be detrimental to the signals of interest integrity.
Table 2 summarizes the characteristics of our ECoG boards for
TBI.
3. MEASURED RESULTS
The high-performance of the proposed neuroelectrochemical
data acquisition platforms has been tested by means of
amperometric and potentiometric experiments. With respect
to the amperometric measurements, an ultra-high precision
current source device (Keithley6221), an electrode for a simple
reduction-oxidation experiment and a glucose biosensor have
been employed (please refer to Figure 2), in order to both
exemplify and quantify the performance of the proposed
TBI instrument. The amperometric experiments have been
performed using the neurochemical board shown in Figure 4B.
With respect to the potentiometric measurements, an ISE has
been fabricated, in order to detect concentration changes in
a given solution (see Figure 2). The ECoG platforms shown
in Figures 5B,C have been tested by employing surrogate
ECoG signals, controlled by a high-precision signal generator,
Agilent33220A that was able to “play-back” in time the artificial
signal and provide it to the ECoG platforms.
3.1. Amperometric Measurements
3.1.1. Ultra-High Precision Current Source
Measurements
The scope of the first experiment is to provide compelling
comparative measurements of the switched-capacitor-based
amperometry front-end of the proposed neurochemical board,
which exploits the DDC family chip vs. a separate traditional
TIA board, which was formerly used by the Boutelle Group
for interfacing with amperometric biosensors. The latter board
incorporates OPA129 amplifiers by Texas Instruments and 1%
tolerance, 10GOhms nominal value resistors, which enable the
read-out of current levels as low as a few tenths of picoAmperes.
Both setups have been tested using the same Keithley6221-
generated currents, ranging from 10 to 100 pAs.
The integration time necessary for the current signal
conversion/digitization has been programmed appropriately for
each current level and in accordance with the fundamental
switched-capacitor equation and the specifications of the chip:
iaverage(t) =
1
TInt
∫ TInt/2
0
∂q(t) =
q(TInt/2)− q(0)
TInt
.
The quantity TInt denotes the total integration period for each
dual switched integrator of the chip (bear in mind Figure 3 and
more specifically Figure 3E).
Figure 6 presents comparative test measurements from the
amperometry section of the neurochemical board and the
OPA129 TIA board. Both front-ends are interfaced with a
Powelab R© visualization suite. The digital code produced by
the DDC114 chip and corresponding to the values of the test
current input signal has been processed and projected through
an output DAC module, located at the “PCB inside a PCB”
electrically isolated part of the neurochemical board (top right
part of Figure 4B). The range of the output voltage of the DAC is
programmable and has been set such that it produces and output
voltage level as close as possible to the one ideally expected by the
OPA129 TIA setup for the given current values.
Comparing Figures 6A,B in conjuction with Figure 6E, it
becomes clear that the DDC114-based amperometry front-end is
characterized by higher SNR than the OPA129-based TIA setup
for the whole range from 10 to 100 pAs. The SNR is improved
by more than 20 dBs. Such an improvement is attributed to
associate with both the absence of the large feedback resistor
(and the thermal noise) and to the fact that the switching
action introduced a sinc filtering action, scalable in the frequency
domain by means of the integration time TInt. In the case of
Figure 6, TInt is programmed to be∼300ms, which corresponds
a first finite frequency notch of ∼3Hz followed by further
notches.
Figures 6C,D provide two and three dimensional
spectrograms for the experiments of Figures 6A,B, respectively,
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FIGURE 5 | The TBI ECoG electronic platforms for the accurate detection of minute electrical brain activities. (A) Operational block diagram of the TBI
ECoG data acquisition platforms. (B) 6-channel ECoG front-end board. (C) The ECoG digital signal processing board.
which confirm the absence of spurious tones in the case of the
proposed amperometry front-end. Referring to Figure 6D, it
becomes clear that the TIA setup suffers from the presence of
several unwanted frequencies corresponding mostly harmonics
of the 50 Hz tone. The combined time- and frequency-domain
results of Figure 6C show that the amperometry modules of
the proposed TBI instrument serve the purpose of enabling the
acquisition of high-quality neurochemical data, which in turn
will attribute to the safer clinical management of the TBI patient.
3.1.2. Electrode Measurements
In order to investigate the high-performance consistency of the
neurochemical board, a second amperometric experiment has
been conducted. This time, a simple Redox couple has been
employed, aiming at testing the neurochemical board operation
in the current range from ∼500 pA to ∼3 nA. The electrode
cell was prepared as previously described (Rogers et al., 2013b).
Briefly, the method of electrode fabrication is to thread platinum
and silver wires through hypodermic needles and epoxy glue
was used to seal them in place. The tip of the needle was
cut and then polished using alumina slurries (1, 0.3, and 0.05
µm sequentially). The platinum wire is used as the working
electrode, the silver wire is chloridized to form a Ag|AgCl
reference electrode and the stainless steel shaft is used as the
auxiliary electrode. Ruthenium hexaamine (Sigma) solutions
were prepared at varying concentrations of 1, 0.5, 0.25, and 0
mM. Prior to taking measurements, each ruthenium hexaamine
solution was bubbled with nitrogen for 20 min. The working
electrode was held at a constant potential of −0.5V vs. Ag|AgCl
for the duration of the experiment. The constant potential
has been provided by an on-board DAC and the on-board
high-accuracy potentiostats (see Figure 4B). The solution was
changed periodically to different concentration levels enabling
the formation of the calibration curve, shown in Figure 7.
3.1.3. Glucose Measurements
The final amperometric experiment describes the interface of
a glucose biosensor used for the monitoring of TBI patients
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TABLE 2 | Electrical characteristics of the ECoG TBI board.
Type of ECoG board
Characteristics Unipolar/bipolar
front-end
Digital signal
processing
Number of input/output channels 6/8 (only input) 14 (only output)
Resolution (bits) 24 16
Data rate (kSPS) 0.5–32 –
Input bias current (pA) 30∗ –
Total analog current supply (mA) 8.35/9.85 17
Total digital current supply (mA) 0.5 17
Boards dimensions (cm) 7 × 5 11 × 14
Medically graded Yes - using power/digital signal/USB isolators
IC controller Spartan3e - 64 MHz - FPGA
Power supply 5V battery 220V AC, 50Hz
*This is the input bias current of the analog circuitry before
the voltage-input ADC.
with the proposed neurochemical board. The working electrode
of the sensor has been connected to the input of the DDC
module, while its counter and reference electrodes have been
appropriately connected to appropriately programmed on-board
potentiostats. For the specific measurement, the concentration
of glucose within a fake microdialysate stream was varied
using an automated LabSmith microfluidic platform. Glucose
oxidase (GOx)(Genzyme), followed by horseradish peroxidase
(HRP) (Genzyme) dissolved into a solution containing 1.5 mM
ferrocene monocarboxylic acid (Fc) (Sigma), was added into the
flow stream containing different concentrations of glucose (100,
75, 50, 25, and 0 µM) and the mixture was then passed over a
combined needle electrode within a microfluidic PDMS flow cell
(please refer to Figure 2). To detect the level of glucose, hydrogen
peroxide generated by the reaction between glucose and GOx,
reacts with the HRP and Fc mixture to form ferrocinium ions,
which can be detected by reduction at the electrode surface,
when that is held at 0.0V vs. Ag|AgCl. The results of the specific
experiment are shown in Figure 8.
At this point, it should be stressed that the trend seems slightly
noisier compared to the measurement of the ideal current input
signal in Figure 6A, since the pumps been used to manipulate
the fluid samples contributed significantly to the overall signal’s
noise levels. The pumpingmotion causes small fluctuations in the
movement of the solution across the surface of the sensor, which
is flow sensitive and hence disturbances in the current signal will
be seen.
3.2. Potentiometric Measurements
Apart from the previous amperometric experiments, an
indicative potentiometric experiment has been also conducted
with the help of the proposed neurochemical circuit. The
specific potentiometric experiment implements a potassium
ISE-neurochemical board interface and demonstrates the faithful
monitoring of the various potassium concentration changes from
the electronic platform. Moreover, in this section, a simulation of
an ECoG measurement will be presented. The “artificial” ECoG
measurement has been conducted with the help of the two ECoG
boards (digital and analog front-end) presented in Figures 5B,C,
respectively.
3.2.1. Potassium ISE
An ISE features an ion-sensing membrane that selectively
binds with the ion of interest, and its output potential is
proportional to the activities (or concentration) of the ion. A
miniaturized potassium ISE had been developed and optimized
in the group and was used in this work. It consisted of a
polymer membrane casted at one end of a polymer electrode
body (perfluoroalkoxyalkane tubing, o.d. 360 µm, i.d. 150 µm),
an internal Ag|AgCl reference electrode and an internal filling
solution of physiological saline. The membrane consisted of
0.2 mg potassium tetrakis(4-chloropheyl)borate, 150.0 mg Bis(2-
ethylhexyl) sebacate, 66.0 mg poly(vinyl chloride) and 2.0 mg
of potassium ionophore. All the chemicals are obtained from
Sigma-Aldrich (UK). The assembled ISEs were stored in aCSF
at 4◦C when not in use. Experimentally, the output voltage of
the ISE was measured against an external Ag|AgCl reference
electrode (saturated at 3 M KCl). The ISEs were calibrated at
25◦C and had a Nernstian sensitivity of ∼59 mV/dec and a
good temporal response for the physiological range of interest.
The potassium ISE has been connected to one of the channels
of the ADS1298, located in the potentiometric section of the
neurochemical board. The results of this experiment are shown
in Figure 9.
3.2.2. Artificial ECoG/SD Signal
The proposed ECoG monitoring system shown in Figures 5B,C
has been tested by means of an “artificial” ECoG/SD signal. This
signal has been recorded from an animal and closely resembles
an actual human ECoG/SD signal. The amplitude of the specific
signal is negative and ∼15 mV from peak-to-peak, a value that
complies with the amplitude of a typical human ECoG/SD signal.
The frequency of the signal has been set to 0.1 Hz, in order
to approximate the frequency of a real SD wave produced by
a human injured brain. The artificial signal has been loaded to
the Agilent33220A signal generator, which was fully controlled
by a PC through USB interface. The whole experiment lasted for
approximately 1 h and a half and included six artificial SD waves.
The 6-channel front-end ECoG board shown in Figure 5B has
been used to record the artificial signal and send it to the main
DSP ECoG board of Figure 5C. The connection between the
boards has been created with the use of an RJ45 cable. Figure 10
illustrates the indicative results obtained from a single channel of
the system. The rest five channels exhibit identical behaviors.
4. DISCUSSION
4.1. Current System Limitations and Future
Improvements
Although the neuroelectrochemical data acquisition system
exhibits remarkable accuracy and very good noise performance,
its high performance amperometric section with the current
input ADC exhibits some limitations. This commercially
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FIGURE 6 | Comparative measurement results using the switched-capacitor-based section of the neurochemical biosensor interfacing circuit board
shown in Figure 4B and a common transimpedance amplifier setup. The current input for both setups is provided by a Keithley6221 current source. (A) DDC
measurements from Keithley6221. (B) I-V measuments from Keithley6221. (C) Two and three dimensional spectrogram of (A). (D) Two and three dimensional
spectrogram of (B). (E) Measure of time-dependent SNR for both setups.
available converter is able to detect very small albeit positive
only input currents, i.e., currents that are “entering” the chip.
Therefore, only reduction currents from a redox electrochemical
reaction can be measured. This may limit the type of biosensors
deployable with this converter. In order to tackle this issue,
in a future version of the proposed neuroelectrochemical
board, a custom-made, current-input ADC integrated circuit
will be designed in standard CMOS process, able to detect
currents flowing bidirectionally (toward and out of the system),
without compromising the system’s total accuracy and low-noise
properties.
With respect to the ECoG analog boards shown in Figure 5B:
their DC-coupled channels allow for the clinical teams to
study the DC level changes while monitoring the ECoG signal.
However, the very probable drift of the ECoG signals might
cause the saturation of the front end electronic system. In order
to prevent this from happening, a DC-level calibration circuit
controller can be introduced. This controller will be able to
monitor the signal’s DC drift rate and adapt in real-time the
system’s DC levels, in order to ensure that the voltage input ECoG
signal will never exhaust the maximum detection levels of the
recording circuitry.
Additional modalities such as wireless transmission, linking
the recorded physiological data with adverse event detection
software installed on a base station can enrich the current
instrumentation platform enabling the monitoring of mobilized
TBI patients (usually 3 days after craniotomy surgery) and
providing a more flexible approach to the early detection and
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FIGURE 7 | Monitoring the time response of the electrode cell shown in Figure 2B for different ruthenium hexaamine concentrations, using the
switched-capacitor amperometry section of the neurochemical biosensor interfacing circuit board, shown in Figure 4. The linear relation between the
ruthenium hexaamine concentrations and the output current of the electrode is shown in the inset of the Figure.
FIGURE 8 | Monitoring the time response of the glucose biosensor shown in Figure 2A for different concentrations, using the switched-capacitor
amperometry section of the neurochemical biosensor interfacing circuit board, shown in Figure 4. The linear relation between the glucose concentrations
and the output current of the biosensor is shown in the inset of the Figure.
subsequent prevention of unwanted patient complication in the
ICU.
The inevitable reduction of biosensor sensitivity over time
means that during long-term monitoring by means of the same
biosensor, the same value of chemical concentration under
detection will provide different electrical readings at different
times. This issue, when left unaddressed, may reduce the clinical
usefulness of the platform as a whole. The problem can be
addressed “head-on” by incorporating an auto-calibration system
which will determine the used sensor’s varying sensitivity at
specific, short intervals and thus ensure the accuracy with which
the monitored concentration levels are detected during long
periods of monitoring. Expectedly, the sensor calibration module
can be configured and controlled wirelessly.
Finally, a new online microfluidic-based sensor system has
been developed for use in combination with a microdialysis
probe. The microfluidic platform is connected to the
microdialysis probe via a 1m connection tubing and sits
on a trolley by the patient bedside. Each sensor is housed on a
micorfluidic chip within an electrode chamber, each containing
68 nL of dialysate. The system currently continuously analyses
the levels of potassium, glucose and lactate within the patient
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FIGURE 9 | Potassium ISE time response for various concentrations, captured by the potentiometry section of the neurochemical biosensor
interfacing circuit board, shown in Figure 4. The linear relation between the logarithm of the potassium concentrations and the output voltage of the system is
shown in the inset of the Figure.
FIGURE 10 | Time response and noise performance results of a simulated ECoG/SD signal generated by Agilent33220A signal generator and recorded
by the ECoG board, shown in Figure 5. (A) Input and amplified output artificial ECoG signal. (B) Two and three dimensional spectrogram of the output signal. (C)
Measure of time-dependent noise factor of the system. (D) Measure of time-dependent noise figure of the system.
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dialysate. This could, in future be expanded to monitor other key
molecules of interest, such as pyruvate or glutamate.
4.2. Conclusions
This paper has presented the design, realization and performance
of novel bioinstrumentation tailored for the collection of
high-quality electrical and neurochemical physiological data
from sedated TBI patients who have undergone craniotomy
surgery and are in danger of suffering from secondary brain
injuries.
Our multi-channel neurochemical instrument supports
the collection of physiological data from both amperometric
and potentiometric biosensors. It enables the acquisition of
low-noise, high-performance amperometric measurements by
means of rapid sampling microdialysis and microfluidics-based
biosensors which can measure the injured brain tissue levels
of glucose and lactate. Our test measurements have confirmed
that our switched capacitor-based amperometry channels are
characterized by superior noise performance when compared
against classic opamp-based transimpedance stages whose
performance and resolution is severely limited by the feedback
resistor-induced thermal noise. Potentiometric potassium
measurements further confirmed the high-performance
operation of our neurochemical instrument. The collection of
glucose, lactate, pyruvate and potassium physiological data has
been identified recently as clinically useful for the treatment of
TBI patients by authoritative consensus statements (Hutchinson
et al., 2015).
Further test measurements have confirmed the ability of our
new multi-channel ECoG instrument to support the collection
of high-quality low-noise electrical ECoG/SD TBI data. Both the
neurochemical and the ECoG instruments are compact in size
and can replace the bulky (∼1m3), trolley-based and impractical
multi-instrument collections with multiple liquid and electrical
connections currently deployed in advanced Neurotrauma ICUs
and used for the monitoring of TBI patients. The new TBI
bioinstrumentation presented here reduces significantly the
connecting wires and tubing between the clinical team and the
patient whilst they are being stabilized. Such a characteristic
is important in the case of multi-trauma patients in need of
emergency treatment since less clutter around the patient allows
more effective the clinicians intervention. Moreover, electrical
and neurochemical physiological data collected by our new TBI
instrumentation will be “fed” in real-time to our adverse event
detection software tailored for TBI patients which, ultimately,
will alert ICU staff to intervene before the onset of secondary
injury, hence allowing for the treatment of the patient in an
effective and timely manner.
In the longer term we see the proposed instrumentation
(and miniaturized variations of its discussed before) as being
key technology for monitoring of stroke patients. This is a
very large patient group who, from our animal studies and
the few patients that have been monitored invasively (e.g.,
hemorrhagic stroke) are at risk of secondary brain injury
detectable by our monitoring strategies. It is our expectation that
such monitoring will define sub-populations of stroke patients
who would benefit from direct neurosurgical intervention
(e.g., decompressive craniectomy). In particular very little
is understood of the pathophysiology of the decompressed
hemisphere. A minimally invasive neuromonitoring system has
the potential to revolutionize our understanding of the needs of
these patients.
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